Skip to main content
. 2010 Mar 23;33(6):1337–1343. doi: 10.2337/dc10-0227

Table 1.

Characteristics of nonproteinuric patients with type 1 diabetes according to whether renal function was stable during 4–6 years of follow-up or early GFR loss developed

Characteristic* Stable renal function Early GFR loss P value
n 276 79
Baseline characteristics
    % men 55 56 0.92
    Age at diabetes diagnosis (years) 17 ± 10 20 ± 11 0.02
    Duration of diabetes (years) 21 ± 9 24 ± 10 0.02
    Age (years) 38 ± 12 44 ± 11 <0.0001
    A1C (%) 8.2 (7.4–9.1) 8.3 (7.6–9.5) 0.17
    Insulin dose (units/kg/day) 0.63 (0.53–0.83) 0.64 (0.48–0.86) 0.83
    BMI (kg/m2) 26 (23–29) 26 (24–32) 0.15
    Serum cholesterol (mg/dl) 184 (166–204) 185 (167–204) 0.96
    Serum HDL (mg/dl) 54 (46–65) 53 (46–64) 0.74
    GFRcystatin (ml/min per 1.73 m2) 131 (116–147) 115 (93–136) <0.0001
    ACR (mg/g) 34.6 (22.2–63.8) 51.6 (29.9–114.9) <0.0001
    % with microalbuminuria 56 75 0.003
    % with renoprotective treatment 50 68 0.005
    Systolic blood pressure (mmHg) 120 (111–128) 122 (114–129) 0.13
    Diastolic blood pressure (mmHg) 70 (68–79) 72 (68–77) 0.60
    Cigarette smoking
        % current 18 13 0.18
        % past 24 34
    Serum uric acid (mg/dl) 4.5 (3.7–5.3) 5.10 (4.4–5.7) <0.0001
Follow-up characteristics
    Duration of follow-up (years) 4.8 (4.1–5.5) 4.9 (3.9–5.7) 0.56
    Number of cystatin determinations 5 (4–6) 5 (4–6) 0.33
    Number of ACR determinations 5 (4–7) 6 (4–7) 0.58
    Last GFRcystatin (ml/min per 1.73 m2) 124 (109–139) 86 (65–99) By design
    Percent change per year in GFRcystatin −1.8 (−2.4 to −1.2) −4.4 (−5.0 to −3.8) By design
    Progressed to CKD stage 3 or greater [n (%)] 3 (1) 19 (24) <0.0001
    Last ACR (mg/g) 17.1 (9.8, 42.1) 40.3 (13.8, 128.5) <0.0001
    Progression of ACR [n (%)] 48 (17) 27 (34) 0.001
    Regression of ACR [n (%)] 103 (73) 26 (33) 0.47

Data are medians (25th–75th percentiles) and P values from Wilcoxon rank sum test for continuous variables (except for age at diabetes diagnosis, duration, and age, which are means ± SD and t tests) and percents with P values from χ2 test for categorical data.

*Values for A1C, serum cholesterol, serum HDL, and ACR were the medians of all determinations during the 2-year interval ending with the entry examination.

†Median of all ACR measurements in the second 2-year follow-up interval.